Theravance Biopharma, Inc. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings
Theravance Biopharma, Inc. (TBPH) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings of $8.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings · last filed 2020-02-27
- Theravance Biopharma, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2017-12-31 was $0.00.
- Theravance Biopharma, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2017-09-30 was $8.00M.
- Theravance Biopharma, Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2017 was $8.00M.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $8.00M derived: sum of 2 quarters · filed 2020-02-27 | $8.00M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $8.00M 10-Q · filed 2018-11-08 | $8.00M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |